Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Thoracic Re-irradiation for Recurrent NSCLC
NCT04275687Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2020
- Primary completion
- Feb 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and nedaplatin in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
docetaxelnedaplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04275687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275687.